Chronic low-grade inflammation often presents not as obvious swelling but as subtle, persistent symptoms. Issues like increased fatigue, difficulty concentrating, poor sleep, and skin problems can be driven by an under-the-radar inflammatory state that even doctors may miss.

Unlike external machines, implanting parts internally triggers the body's powerful defenses. The immune system attacks foreign objects, and blood forms clots around non-native surfaces. These two biological responses are the biggest design hurdles for internal replacement parts, problems that external devices like dialysis machines don't face.

Transferring a healthy person's stool can shut down severe infections like C. diff almost overnight. This procedure is a powerful alternative to major surgery or failed antibiotic treatments, showcasing the gut microbiome's critical role in immune function.

Alzheimer's can be understood as a vascular disease rooted in nitric oxide deficiency. This decline impairs blood flow, glucose uptake, and inflammation regulation in the brain. Therefore, strategies to restore nitric oxide address the physiological root causes of the disease, not just the symptoms like plaque buildup.

The rise in consumer cleaning products and spick-and-span households reduces our exposure to diverse microbes. According to the hygiene hypothesis, this lack of immune system training can make our bodies less robust and more prone to overreacting to benign substances like food proteins, thus fostering allergies.

Early researchers were overwhelmed by the massive, chaotic changes in gene expression in sepsis patients, terming it a "genomic storm." Inflammatics' founders viewed this complexity not as an obstacle but as a rich dataset. By applying advanced computational analysis, they identified specific, interpretable signals for diagnosis and prognosis.

Medicine excels at following standardized algorithms for acute issues like heart attacks but struggles with complex, multifactorial illnesses that lack a clear diagnostic path. This systemic design, not just individual doctors, is why complex patients often feel lost.

Sepsis is not a monolithic condition. The failure of more than 100 immunomodulatory drug trials is likely because they treated all patients the same. The future of sepsis treatment mirrors oncology: subtyping patients based on their specific inflammatory profile to match them with a targeted therapy.

Developing an antibiotic is costly, but its use is short-term and new drugs are held in reserve, making them unprofitable. This market failure, not a lack of scientific capability, has caused pharmaceutical companies to exit the space, creating a worsening global health crisis.